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ﻉﺍﻮﻧﺃﻒﻠﺘﺨﻣﺝﻼﻌﻟﻊﺳﺍﻭﻕﺎﻄﻧﻰﻠﻋﺯﺎﻨﻴﻛﻦﻳﺯﻭﺮﻴﺘﻟﺍﺕﺎﻄﺒﺜﻣﻡﺪﺨﺘﺴﺗ
ﺭﺎﺛﻵﺍﻭ.ﻲﺿﺎﻤﻟﺍﻥﺮﻘﻟﺍﻦﻣﺕﺎﻨﻴﻌﺴﺘﻟﺍﺮﺧﺍﻭﺃﻲﻓﺎﻬﺑﻞﻤﻌﻟﺍﺀﺪﺑﺬﻨﻣ،ﺕﺎﻧﺎﻃﺮﺴﻟﺍ
ﺕﺎﻴﺑﺩﻷﺍﻲﻓﺍﺪﻴﺟﺔﻘﺛﻮﻣ،ﺯﺎﻨﻴﻛﻦﻳﺯﻭﺮﻴﺘﻟﺍﺕﺎﻄﺒﺜﻣﺪﺣﺃ،ﺐﻴﻨﻴﺗﺎﻤﻳﻺﻟﺔﻴﺒﻧﺎﺠﻟﺍ
.ﺪﺒﻜﻟﺍﺕﺎﻤﻳﺰﻧﺇﻝﻼﺘﺧﺍﻭ،ﻲﻤﻈﻌﻟﺍﻉﺎﺨﻨﻟﺍﺖﺒﻛﻭ،ﻱﺪﻠﺠﻟﺍﺢﻔﻄﻟﺍﻭ،ﺩﺎﻬﺟﻹﺍﻞﻤﺸﺗﻭ
ﻲﺘﻟﺍﺕﺎﺣﻮﺴﻤﻟﺍﻰﻠﻋﻦﻴﻓﺮﺸﻤﻟﺍﻦﻣﺓﺭﺩﺎﻨﻟﺍﺔﻴﺒﻧﺎﺠﻟﺍﺭﺎﺛﻵﺍﻦﻋﺓﺪﻋﺮﻳﺭﺎﻘﺗﺖﺒﺘﻛ
.ﻥﻮﺴﻧﻮﺟﻦﻔﻴﺘﺳﺔﻣﺯﻼﺘﻣﻭﻲﺒﻠﻘﻟﺍﻙﺎﻛﺪﻟﺍﻞﺜﻣ،ﻖﻳﻮﺴﺘﻟﺍﺪﻌﺑﺎﻣﺔﻠﺣﺮﻣﻲﻓﺖﻳﺮﺟﺃ
ﺔﻄﺒﺗﺮﻤﻟﺍﻲﻋﺎﻨﻤﻟﺍﺔﻳﻮﻣﺪﻟﺍﺢﺋﺎﻔﺼﻟﺍﺺﻘﻨﻟﺓﺭﺩﺎﻧﺔﻟﺎﺤﻟﺽﺮﻌﻧ،ﺮﻳﺮﻘﺘﻟﺍﺍﺬﻫﻲﻓ
ﺔﻠﺛﺎﻤﻣﺕﻻﺎﺤﻟﺰﺟﻮﻣﺢﻴﺿﻮﺗﻊﻣ.ﻦﻄﺒﻟﺍﻞﺧﺍﺩﺩﺎﺣﻑﺰﻧﻰﻟﺇﺕﺩﺃﺐﻴﻨﻴﺗﺎﻤﻳﻹﺎﺑ
.ﺯﺎﻨﻴﻛﻦﻳﺯﻭﺮﻴﺘﻟﺍﺕﺎﻄﺒﺜﻣﺎﻬﺘﺒﺒﺳﻲﻋﺎﻨﻤﻟﺍﺔﻳﻮﻣﺪﻟﺍﺢﺋﺎﻔﺼﻟﺍﺺﻘﻧﻦﻣ
؛ﺯﺎﻨﻴﻛﻦﻳﺯﻭﺮﻴﺘﻟﺍﺕﺎﻄﺒﺜﻣ؛ﺔﻳﻮﻣﺪﻟﺍﺢﺋﺎﻔﺼﻟﺍﺺﻘﻧ:ﺔﻴﺣﺎﺘﻔﻤﻟﺍﺕﺎﻤﻠﻜﻟﺍ
ﺮﻴﻗﺎﻘﻌﻟﺍﻦﻋﺞﺗﺎﻨﻟﺍﺔﻳﻮﻣﺪﻟﺍﺢﺋﺎﻔﺼﻟﺍﺺﻘﻧ؛ﻲﻤﻈﻌﻟﺍﻉﺎﺨﻨﻟﺍﺖﺒﻛ؛ﺐﻴﻨﻴﺗﺎﻣﻹﺍ
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Tyrosine kinase inhibitors (TKIs) have played an indis-
pensable role in the treatment of various haematological and
solid organ malignancies. The blocking pathological tyrosine
kinase activity results in the arrest of oncogenic pathway that
drives the growth of cancer cells. The first TKI that was
introduced was imatinib mesylate, which has been used in
treatment of various diseases, including chronic myeloid
leukaemia (CML), Phþ acute lymphoblastic leukaemia
(ALL), and gastrointestinal stromal tumours (GIST). These
agents are not free from adverse effects. Side effects, such as
myelosuppression (or hypo-/amegakaryocytic thrombocy-
topenia), have been noted to affect up to 45% of imatinib
recipients1 and have also been described for other TKIs such
as sunitinib.2,3 Clinical trials have shed light on the commonhis is an open access article under the CC BY-NC-ND license
16/j.jtumed.2015.01.005
M. Radwi and C. Cserti-Gazdewich366side effects associated with TKIs; however, rarer side effects,
such as autoimmune phenomena, have only become
apparent in postmarketing reports (e.g., cardiac
tamponade). We present a rare complication of the use of
imatinib that caused drug-induced immune thrombocyto-
penia (DIT) in a patient with a gastrointestinal stromal
tumour (GIST) and a summary of similar cases.
Case
A72-year-old femalepatientwas startedon imatinib400mg
PO daily for an advanced gastrointestinal stromal tumour
(GIST) with liver metastasis. Her medical history was unre-
markable for any autoimmune,HIV, hepatitis B orC infection
or any bleeding disorders. She denied any alcohol use and any
history of recreational drug use. Her baseline complete blood
count (CBC) revealed the following: white blood cell count
(WBC), 6.91 109/L (normal4e11);haemoglobin (Hb), 128g/
L (normal 120e160); and platelets, 226 109/L (normal 150e
400). Less than four weeks later after beginning imatinib, she
sought medical attention after developing a generalized pete-
chial rashand rightupperquadrant (RUQ)pain.Onher arrival
to the emergency room, her CBC revealed severe thrombocy-
topenia (platelets 10  109/L), a WBC count of 3.74  109/L
and anaemia (Hb 107 g/L).
Investigations
The possible causes of the acute onset of thrombocyto-
penia were investigated. Disseminated intravascular coagu-
lation (DIC) and thrombotic microangiopathy (TMA) were
unlikely and were excluded based on a normal coagulation
profile, a peripheral blood smear examination that revealedFigure 1: Temporal profile of association between tyrosinno evidence of schistocytes and normal lactate dehydroge-
nase (LDH) levels. She was not exposed to heparin prior to
admission, and thus it was unlikely that she had developed
heparin-induced thrombocytopenia (HIT).
Her next CBC revealed a Hb level of 76 g/L, a WBC of
2.76  109/L and a platelet count of 2  109/L. Additionally,
her reticulocyte count (103.4  109/L) and immature retic-
ulocyte fraction (33.9%) were both elevated. Due to a strong
suspicion of possible intra-abdominal bleeding, she under-
went a contrast CT scan of her abdomen, which confirmed
intraperitoneal bleeding from the superior intra-renal artery.
This finding explained her new onset RUQ pain and the drop
in haemoglobin.Treatment
The patient underwent a successful embolization of the
culprit vessel to stop the bleeding. After excluding common
causes of acute onset of thrombocytopenia, imatinib-
associated immune thrombocytopenia was suspected
because this drug had recently been initiated prior to her
presentation; thus, imatinib was immediately stopped. Due
to the seriousness of the thrombocytopenia (platelet count of
2  109/L with severe bleeding), treatments of prednisone
1 mg/kg PO once daily, intravenous immunoglobulin (IVIG)
2 g/kg over two days, and supportive transfusion with
packed red blood cells and platelets with evidence of
refractoriness to platelet transfusions were simultaneously
initiated. Additionally, the patient also received a single 2-mg
dose of vincristine. Following the cessation of imatinib and
the introduction of these immunomodulation measures, her
platelet count exhibited an initial recovery within eight days
to 31 109/L and ultimately reached 138 109/L at the timee kinase inhibitor use, blood counts, and treatments.
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TKI related drug-induced immune thrombocytopenia 367of discharge. At this point, she was put on prednisone at a
dose that tapered at a rate of 10 mg per week. One month
after stopping the corticosteroid, her platelet count was
stable at 208 109/L, and there was no evidence of recurrent
thrombocytopenia (Figure 1). The Naranjo probability for
this sequence having represented a drug-associated adverse
drug reaction (ADR) was calculated to be 6 and therefore
deemed probable.4T
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Several mechanisms have been implicated in drug-induced
thrombocytopenia (DIT) including accelerated platelet
destruction caused by drug-dependent antibodies,5 decreased
platelet production,6 and reactivity with drug metabolites.7
DIT can be benign if the thrombocytopenia occurs without
harm and is followed by spontaneous recovery upon
discontinuation of the offending drug. Conversely, DIT
might manifest with serious results as in the case of
heparin-induced thrombocytopenia with thrombosis, which
require the initiation of an alternate anticoagulant.8e10 The
diagnosis of DIT is similar to that of ITP in that they are
both diagnoses of exclusion; thus, other causes of
thrombocytopenia need to be ruled out.11
Clinical features thatmight aid differentiationofDIT from
other causes of thrombocytopenia include the following: the
degree of thrombocytopenia, the presence of bleeding, and the
temporal relationshipbetween the onset of thrombocytopenia
and initiation of the culprit drug.12 Other features include
immediate platelet transfusion refractoriness13 and
demonstrable anti-platelet antibodies.12 Thrombocytopenia
is usually severe, and almost invariably associated with
bleeding events. Drug imputability is suggested by the
temporal association (with consistent post-exposure induc-
tion and durable remission after cessation) and specialized
(but not widely available) in-vitro demonstrations of the anti-
platelet activity in drug-treated platforms.12
Although our diagnostic capability for DIT in the present
casewas limited by the deferral of a bonemarrow examination
and serologic studies, our patient’s case nevertheless exhibited
the other elements of DIT, such as the degree of thrombocy-
topenia and refractoriness to platelet transfusion. Other cases
of imatinib use have resulted in immune haemolytic anaemia
and DIT.14,17 The present case is the second published report
of imatinib-induced thrombocytopenia. Although serologic
testing for DIT was deferred in this case, Rajappa et al.18
reported a case of imatinib-associated thrombocytopenia,
which was definitive based on four criteria for the diagnosis of
drug-induced thrombocytopenia.15
To our knowledge, there have been five other reported
cases of severe thrombocytopenia with TKI administration
(Table 1). The majority (80%) were related to the use of
newer TKIs (e.g., sorafenib and sunitinib). As in the
present case, the onsets of thrombocytopenia were not
immediate but were rather delayed (by a mean of seven
weeks). Thrombocytopenia is often sufficiently severe to
require interventions, such as platelet transfusions, albeit
no fatalities have yet been reported. Distinguishing
between ITP and DIT can be difficult because some
diseases for which TKIs are administered, such as renal cell
carcinoma, can themselves be associated with ITP.16,17
M. Radwi and C. Cserti-Gazdewich368However, a definitive post-cessation resolution (within 1e3
weeks) is most consistent with DIT.
In summary, this updated assembly of cases illustrates
DIT of a likely immune nature that is secondary to various
TKIs. This ADR requires a high index of suspicion for
treating physicians to recognize it and act promptly to
mitigate any morbidity or mortality.
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